Several clinical trials have demonstrated that anti-IL-5(R) biologics were able to improve lung function, asthma control and chronic oral corticosteroid exposure and reduce exacerbations among eosinophilic asthmatic patients. However, a certain variability in clinical responses to anti-IL-5(R) biologics was brought to light. Our study aimed at evaluating the role of baseline sputum eosinophils in identifying super-responders to mepolizumab and benralizumab. Our study reinforces the importance to examine sputum eosinophils in patients suffering from severe asthma before starting a biologic as it is associated with the intensity of response to mepolizumab and benralizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715510 | PMC |
| http://dx.doi.org/10.1136/thorax-2022-219781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti-IL-5R Therapy and Requiring Class Switching to Anti-IL-4/13.
Int Forum Allergy Rhinol
January 2025
Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.
Background: Type 2 inflammation dominates eosinophilic chronic rhinosinusitis (eCRS) and adult onset asthma. IL-4, -5, and -13 are prominent disease mediators. Disease control can be achieved with biologic therapies.
View Article and Find Full Text PDFTargeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents.
Allergy
November 2024
Pulmonary Department, Mainz University Hospital, Mainz, Germany.
Article Synopsis
- * Interleukin-5 (IL-5) is crucial in the activation and survival of eosinophils, making it an essential target for treatments aimed at severe asthma, with therapies like mepolizumab and reslizumab blocking IL-5, while benralizumab targets its receptor for enhanced efficacy.
- * Despite the lack of direct comparative trials for these therapies, research continues to explore the differences between partial and complete eosinophil depletion, highlighting the ongoing debate about their clinical significance in treating eosinophilic asthma. *
Biologic therapy for food allergy.
J Food Allergy
September 2020
From the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, California, and.
With the rising prevalence, food allergies have become a significant health burden that affects 6% to 13% of the global population. Although oral immunotherapy (OIT) has been promising for food allergies, this therapy has limitations, including high rates of adverse reactions and long treatment periods. Biologics may address these limitations by increasing the safety and tolerability of OIT and decreasing treatment periods.
View Article and Find Full Text PDFSevere Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.
Medicina (Kaunas)
February 2024
Pulmonology Department, Infectious Diseases and Pulmonology Hospital "Victor Babes" Timisoara, 300310 Timisoara, Romania.
Article Synopsis
- Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation can be challenging to differentiate in smokers, as both conditions have similar clinical presentations.
- A case report of a 67-year-old former smoker illustrates how a patient with severe eosinophilic asthma showed significant improvement in lung function after treatment with the anti-IL5R monoclonal antibody benralizumab, despite initial diagnostic challenges.
- The patient achieved clinical remission, with marked improvement in lung function, although some residual airway obstruction remained, highlighting the effectiveness of targeted therapy for severe eosinophilic asthma.
Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
J Asthma
August 2024
Medicine Department, Universidad Autónoma de Madrid, Madrid, Spain.
Objective: The aim of this retrospective multicentre study is to describe the clinical characteristics of patients diagnosed with severe eosinophilic asthma receiving anti-IL-5/anti-IL-5Rα therapies and to compare their effectiveness.
Methods: We collected and analysed results separately for anti-IL-5 and anti-IL-5Rα therapies from January 2016 until December 2021 in multidisciplinary severe asthma units. We collected demographic and clinical data, treatment with previous anti-IgE and/or anti-IL-5 agents, and comorbidities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!